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Histone modifications play important roles in multi-
ple physiological processes by regulating gene
expression. However, the roles of histone modifica-
tions in immunity remain poorly understood. Here
we report that Ash1l, a H3K4methyltransferase, sup-
pressed interleukin-6 (IL-6), and tumor necrosis
factor (TNF) production in Toll-like receptor (TLR)-
triggered macrophages, protecting mice from
sepsis. Ash1l-silenced mice were more susceptible
to autoimmune disease as a result of enhanced IL-6
production. Ash1l enhanced A20 expression through
induction of H3K4 modification at the Tnfaip3
promoter via H3K4 methyltransferase activity of
Ash1l SET (Su[var]3-9, E[z] and trithorax) domain.
Ash1l suppressed NF-kB, mitogen-activated protein
kinase (MAPK) pathways, and subsequent IL-6 pro-
duction via facilitating A20-mediated NF-kB signal
modulator NEMO and transducer TRAF6 deubiquiti-
nation. Therefore, Ash1l-mediated H3K4 methylation
at the Tnfaip3 promoter is required for controlling
innate IL-6 production and suppressing inflamma-
tory autoimmune diseases, providing mechanistic
insight into epigenetic modulation of immune re-
sponses and inflammation.
INTRODUCTION
Toll-like receptors (TLR) are critical for pathogen recognition and
host defense against infections. Innate immune cells such as
macrophages sense invading microbial pathogens via TLRs to
induce downstream signaling cascades, subsequently leading
to production of proinflammatory cytokines and interferons
(IFNs) (Takeuchi and Akira, 2010; Kawai and Akira, 2010). The
physiological importance of TLR signaling is underscored by
the involvement of TLRs and their major signaling components470 Immunity 39, 470–481, September 19, 2013 ª2013 Elsevier Inc.in human diseases, including cancer and immunological dis-
eases (Netea et al., 2012; Ben-Neriah and Karin, 2011).
Regarding the latter, aberrant TLR signals have been associated
with various inflammatory diseases, such as endotoxin shock,
rheumatoid arthritis (RA), and inflammatory bowel disease
(Marshak-Rothstein, 2006). Thus, negative regulation of TLR
signaling is essential for avoiding excessive inflammatory
immune responses and maintaining immune homeostasis. To
date, a number of intracellular molecules and inhibitory recep-
tors have been identified to be involved in the control of TLR
signaling, such as the adaptor molecule TANK and the myeloid
surface receptor CD11b (Kawagoe et al., 2009; Han et al.,
2010; Liew et al., 2005).
Accumulating studies have suggested the critical involvement
of ubiquitination and its regulatory enzymes in the regulation of
TLR signaling (Hu et al., 2013). In particular, a ubiquitin-editing
enzyme, A20, has emerged as a potent TLR-negative regulator
that functions by removing ubiquitin chains fromNF-kB essential
transducer TRAF6 (Boone et al., 2004). The pivotal regulatory
role of A20 has been confirmed by its involvement in protecting
hosts from endotoxin shock and TLR4-dependent erosive poly-
arthritis (Matmati et al., 2011; Ma and Malynn, 2012). Consid-
ering the essential role of negative regulators in immune balance,
identification, and characterization of the unknown regulators of
TLR signals will better elucidate the regulatory mechanism of
TLR-triggered inflammatory responses and will provide impor-
tant clues for prevention and treatment of inflammatory and
autoimmune diseases.
Epigenetic modifications are hereditable transcriptional regu-
lation of genes without altering genome DNA sequence and play
essential roles in a variety of biological and pathological pro-
cesses (Portela and Esteller, 2010), including DNA methylation,
histone modification and chromatin remolding. In particular,
aberrant histone modifications are tightly associated with the
pathogenesis of multiple human diseases (Feinberg, 2007), and
some of them have been proven to be potential diagnostic
biomarkers or therapeutic targets for inflammatory diseases,
such as marked histone H3 deacetylation in oligodendrocytes
within early-stage multiple sclerosis lesions (Koch et al., 2013)
and aberrant histone methylation and acetylation mediated by
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Ash1l Is an Inhibitor of TLR Responsesmethyl-CpG-binding protein 2 in the pathogenesis of RA (Miao
et al., 2013). Lysine methylation is one of the most characterized
histone modifications to date. In particular, H3K4 methylation
associated with transcriptional activation plays critical develop-
mental roles by mediating mitotic inheritance of lineage-specific
gene expression such as Hox and Tbx families (Schuettengruber
et al., 2007).
Up to now, 14 H3K4 methyltransferases and demethylases
have been identified (Allis et al., 2007), some of which have
been associated with immune cell differentiation and function
(Krivtsov and Armstrong, 2007). For example, Mll1 can specif-
ically accumulate at the Gata3 locus of memory T helper 2 (Th2)
cells, but not naive T cells, and is therefore essential for the
expression of Gata3 and Th2 cell-associated cytokines such as
interleukin-4 (IL-4) (Nakata et al., 2010). However, the detailed
roles of H3K4methyltransferases and demethylases in immunity,
especially in TLR-mediated innate immune responses, remain
poorly understood. Better understanding of the function of these
enzymes in innate immunity and the pathophysiology of relevant
diseases, aswell as the underlyingmechanisms,will provide new
insight into the epigenetic regulation of immune responses.
The primary goal of the current study is to understand the role
of H3K4 methyltransferases and demethylases in regulating
innate inflammatory immune responses. For this purpose, we
performed a screening test by silencing the 14 kinds of enzymes
involved in H3K4 methylation in mouse peritoneal macrophages
with specific small interfering RNAs (siRNAs) and then measured
lipopolysaccharide (LPS)-induced IL-6 production. Through this
systematic study, we found that siRNA targeting Ash1l ([absent,
small, or homeotic]-like [Drosophila]) increased LPS-induced
production of IL-6. Ash1l is the mammalian homolog of
Drosophila Ash that contains a conserved SET (Su[var]3-9, E[z]
and trithorax) domain and acts as an activator of various genes
such as Ubx and HOXA10 via its H3K4 methylation activity of
the SET domain (Byrd and Shearn, 2003; Gregory et al., 2007).
Ash1l may regulate early T cell development via its plant homeo-
domain-like zinc (PHD) finger (Tanaka et al., 2008). So far, there is
no report about the role of Ash1l in innate inflammatory immune
responses. To study the biological role of Ash1l in immunological
process in vivo, we generated Ash1l-silenced mice via piggy-
back (PB) transposon insertion. Interestingly, Ash1l-silenced
mice were more susceptible to endotoxin shock, sepsis, and
the development of autoimmune diseases. We demonstrated
that Ash1l suppressed TLR-triggered IL-6 production by directly
enhancing A20 expression via inducing H3K4 modification at the
Tnfaip3 promoter. The negative regulatory role of Ash1l in innate
inflammatory immune response was dependent on its H3K4
methyltransferase activity of the SET domain. Our results eluci-
date a crucial role of Ash1l in the negative regulation of TLR-trig-
gered innate inflammatory immune response and suppression of
autoimmune diseases, providing an insight into the mechanisms
of epigenetic modulation of immune responses.
RESULTS
Silencing of Ash1l Increases TLR4- and TLR3-Triggered
Proinflammatory Cytokine Production in Macrophages
TLR-induced proinflammatory cytokines are critical pathological
mediators of various autoimmune diseases. In particular, IL-6Imblockage has been verified as effective treatment for human
RA (Tanaka and Kishimoto, 2012). Fourteen kinds of enzymes
that modify H3K4methylation have been identified and classified
as methyltransferases and demethylases. To screen for the
enzymes that might be involved in innate inflammatory immune
responses, we transfected mouse peritoneal macrophages
with specific siRNAs respectively designed for these enzymes
and then measured LPS-induced IL-6 production. Among the
siRNAs test (see Table S1 available online), the one silencing
Ash1l (Figure 1A) increased the production of IL-6 and tumor
necrosis factor (TNF) in macrophages stimulated by the TLR3
and TLR4 ligands, poly(I:C) and LPS (Figures 1B and 1C). How-
ever, the Ash1l silencing did not affect IFN-b production induced
by LPS or poly(I:C) (Figure S1A). Silencing of several other meth-
yltransferases, such as Mll1, Mll2, and Mll4 and the demethylase
Kdm5a also altered IL-6 production, but this result was much
milder compared to that obtained from the Ash1l silencing and
expected from the previously proposed roles of some methyl-
transferases and demethylases in the activation or inhibition of
gene expression (Wang et al., 2012; Austenaa et al., 2012) (Table
S1). We hence selected Ash1l for further investigation for its un-
expected effects in inhibiting LPS-induced IL-6 production as a
histone methyltransferase.
On the basis of the screening system, we next investigated the
expression profiles of Ash1l in immune system. Ash1l was widely
expressed in multiple organs, with particular abundant in brain,
kidney, and heart (Figure S1B). Ash1l was also widely expressed
in various immune cells, with preferential expression in CD4+
T cells, NK cells, and peritoneal macrophages (Figure S1C).
Moreover, LPS upregulated Ash1l and induced its accumulation
in both cytoplasm and nucleus of macrophages (Figures S1D
and S1E).
To further investigate the role of Ash1l in TLR-triggered innate
inflammatory response, we generated Ash1l-silenced mice via
inserting the PB transposon between exons 15 and 16 of Ash1l
allele (Figure S2A) and confirmed the successful silence of
Ash1l expression in Ash1l-silenced mouse peritoneal macro-
phages (Figures S2B and S2C). The frequency of T cells, B cells,
dendritic cells, NK cells, neutrophils, and F4/80+CD11b+ macro-
phages in the splenocytes was similar between Ash1l-silenced
mice and wild-type (WT) littermate mice (Figure S2D). The pro-
portion and total number of peritoneal macrophages and
in vitro generated bone marrow-derived macrophages (BMDMs)
were also normal in Ash1l-silenced mice (Figure S2E). Though
Ash1l was shown to regulate certain genes involved in cell-fate
determination in K562 cells (Tanaka et al., 2011), we did not
observe any difference in those genes, including integrin alpha
2b (Itga2b) and integrin beta 3 (Itgb3), in LPS-stimulated
RAW264.7 cells after Ash1l silencing (Figure S2F). Therefore,
silencing of Ash1l does not affect differentiation of lymphoid
and myeloid immune cell subsets.
Notably, in response to LPS or poly(I:C) stimulation, peritoneal
macrophages and BMDMs from Ash1l-silenced mice produced
more IL-6 and TNF than those derived from the WT mice (Fig-
ures 1D and 1E), thus confirming the results obtained from
the in vitro Ash1l-silencing studies. Therefore, silencing of
Ash1l enhances TLR-triggered production of proinflammatory
cytokines in macrophages, whereas it has no effect on macro-
phage differentiation.munity 39, 470–481, September 19, 2013 ª2013 Elsevier Inc. 471
Figure 1. Silencing of Ash1l Enhances TLR-
Triggered Production of Proinflammatory
Cytokines in Macrophages
(A) Protein (top) and mRNA (bottom) amounts of
Ash1l in peritoneal macrophages 48 hr after
transfection with control siRNA (Ctrl siRNA) or
siRNA specific for Ash1l (Ash1l siRNA).
(B) IL-6 and TNF mRNA amounts of macrophages
transfected as in (A), then stimulated for 4 hr with
PBS, LPS (100 ng/ml), or poly (I:C) (10 ug/ml).
(C) CBA assay of IL-6 and TNF in supernatants of
macrophages transfected as in (A), stimulated for
8 hr with PBS, LPS, or poly (I:C).
(D and E) CBA assay of IL-6 and TNF in superna-
tants of WT and Ash1l-silenced peritoneal mac-
rophages (D) and BMDMs (E) stimulated as in (C).
Error bars represent SD. *p < 0.05, **p < 0.01.
These data sets are representative of three inde-
pendent experiments. Related to Figure S1 and
Table S1.
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Ash1l Is an Inhibitor of TLR ResponsesAsh1l-Silenced Mice Exhibit Increased Acute
Inflammation in Response to TLR-Ligands Challenge
and E. coli Infection
To further confirm the effect of Ash1l on TLR-triggered innate in-
flammatory response, we challenged Ash1l-silenced mice with
TLR ligands or Gram-negative bacteria Escherichia coli (E. coli)
in vivo. Compared to WT mice, Ash1l-silenced mice produced
significantly higher IL-6 and TNF in serum after being challenged
with LPS or poly(I:C) (Figure 2A). Upon E. coli infection, the
Ash1l-silenced mice also produced more IL-6 and TNF (Fig-
ure 2B) and had a higher bacterial load in the blood than WT
mice (Figure 2C), which is in accordance with previous studies
showing that proinflammatory cytokines such as TNF promote
the dissemination of E. coli (Han et al., 2010). Following sublethal
challenge with E. coli, the Ash1l-silenced mice displayed mark-
edly reduced survival (Figure 2D). Furthermore, we observed
more severe inflammatory hyperemia in the lungs of Ash1l-
silencedmice as characterized by increased infiltration of mono-
nuclear cells and red blood cells 6 hr after challenge with E. coli
or LPS (Figure 2E). Thus, Ash1l-silenced mice developed a more
severe innate inflammatory response andweremore susceptible
to endotoxin shock and E. coli-induced sepsis. These data indi-472 Immunity 39, 470–481, September 19, 2013 ª2013 Elsevier Inc.cate that Ash1l negatively regulates the
innate inflammatory response, including
suppression of innate IL-6 production,
both in vitro and in vivo.
Ash1l-Silenced Mice Have
Increased Susceptibility to
Pathogenesis of Autoimmune
Disease
A previous study found that Ash1l gene is
located in the murine type I diabetes
locus Idd17 and becomes upregulated
in NOD mice, suggesting a potential role
of Ash1l in self-tolerance (Zucchelli
et al., 2005). We thus wondered whether
Ash1l might also be involved in the path-ogenesis of autoimmune disease. We detected higher immuno-
globulin M (IgM), IgG1, IgG2a, IgG2b, and IgA, but intact IgG3 in
serum of 8-month-old Ash1l-silenced mice compared with litter-
mate WT mice (Figure 3A).The concentration of IL-6 in serum of
8-month-oldAsh1l-silencedmicewasalsoelevated (FigureS3A).
Histological analysis revealed more severe infiltration of mono-
nuclear cells in various organs of aged Ash1l-silenced mice (Fig-
ure 3B). Moreover, the aged Ash1l-silenced mice exhibited
increased susceptibility to membranous glomerulonephritis
with more thickened and prominent capillarity loops, which can
be linked to a chronic infectious diseases or systemic lupus ery-
thematosus (SLE). In addition, we also observed more deposi-
tion of immune complexes of autoantibodies in the glomerulis
of aged Ash1l-silenced mice (Figure 3C). These data indicate
that aged Ash1l-silenced mice were more prone to spontaneous
autoimmune disease, suggesting Ash1l has functional roles in
protecting mice from spontaneous autoimmune disease.
We further investigated the effect of Ash1l on autoimmunity
development by comparing the incidence and severity of
collagenII-induced arthritis (CIA) in Ash1l-silenced and control
mice. CIA is a well-established animal model for human RA,
both involving IL-6 as a critical mediator of the initiation and
Figure 2. Ash1l-Silenced Mice Are More
Susceptible to TLR Ligands Challenge and
E. coli-Induced Sepsis
(A) CBA assay of IL-6 and TNF in serum of WT and
Ash1l-silenced mice (n = 5 per genotype) 3 hr after
intraperitoneal injection of LPS (15 mg per kg body
weight) or poly (I:C) (20 mg per kg body weight).
(B and C) CBA assay of IL-6 and TNF in serum (B)
and bacterial load in blood (C) of WT and Ash1l-
silenced mice (n = 5 per genotype) treated intra-
peritoneally with 13 108 E. coli (strain O111:B4) for
4 hr and 8 hr, respectively. Error bars represent SD
(B). Each symbol represents an individual mouse,
small horizontal lines for the mean (C). *p < 0.05,
**p < 0.01.
(D) Survival of WT and Ash1l-silenced mice (n = 10
per genotype) infected with 53 107 E. coli. p < 0.05
(Wilcoxon test).
(E) Hematoxylin and eosin staining of lungs from
WT and Ash1l-silenced mice 6 hr after challenge
with PBS or LPS as in (A), or with E. coli as in (B).
Scale bars represent 20 mm. Original magnifica-
tion is 3100. These data sets are representative
of three independent experiments. Related to
Figure S2.
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Ash1l Is an Inhibitor of TLR Responsesdevelopment of the diseases. Uponmonitoring of disease devel-
opment, we observed higher incidence of Ash1l-silencedmice to
CIA accompanied by increased thickness in hind ankle joints and
more severe swelling in the paws, as compared to their WT litter-
mates (Figures 4A–4C; Figure S3B). The concentration of IL-6 in
serum of Ash1l-silenced mice with CIA was also elevated (Fig-
ure S3C). Histological analysis of knee joints also depicted
more severe cartilage and bone destruction and mononuclear
cells infiltration in joint capsule in Ash1l-silenced mice upon
CIA induction (Figure 4D). Together, these data suggest that
Ash1l-silenced mice are more susceptible to CIA induction.
Ash1l Attenuates the Pathogenesis of Autoimmune
Disease Partially by Controlling IL-6 Production
Given the excessive IL-6 in serum of Ash1l-silenced mice at
8 months of age or under CIA induction, as well as the certifi-
cated correlation between IL-6 production and arthritis severity,
we surmised that the excessive IL-6might contribute to themore
susceptibility of Ash1l-silenced mice to autoimmune disease. To
examine this possibility, we generated Ash1l-silenced Il6/
double-mutant mice and observed that the severe infiltration ofImmunity 39, 470–481, Semononuclear cells in various organs of
aged Ash1l-silenced mice was reduced
in aged Ash1l-silenced Il6/ double-
mutant mice (Figure S3D). We also further
investigated the role of IL-6 in the regula-
tion of CIA by Ash1l. Consistent to the
previous studies, we observed that the
Il6/ mice were significantly more resis-
tant to CIA induction, as shown by the
lack of disease incidence and the normal
joints during the whole monitoring pro-
cess (Figures 4E–4H; Figure S3E). Ash1l-
silencedmice developed themost seriousarthritis, showing the highest incidence and clinical scores,
thickest ankle joints, and most serious cartilage and bone
destruction. Importantly, these severe pathological symptoms
of the Ash1l-silenced mice were substantially reduced after
they were crossed with the Il6/ mice (Ash1l-silenced Il6/
double-mutant mice) (Figures 4E–4H; Figure S3E). These data
suggest that IL-6 is necessary for the development of CIA
and Ash1l potentially prevents the development of CIA via the
suppression of IL-6. Interestingly, Ash1l-silenced Il6/ double-
mutant mice were still more susceptible to CIA than Il6/
mice, which indicate that some other factors besides IL-6 might
be also involved in the exaggerated CIA development in Ash1l-
silenced mice, which needs further investigation.
Ash1l Suppresses TLR- and TNF-Triggered NF-kB and
MAPK Pathways
NF-kB andMAPK signaling pathways are critical for IL-6 produc-
tion in response to TLR and TNF stimulation. To investigate the
molecular mechanism by which Ash1l negatively regulates
TLR-triggered IL-6 production, we examined the key signaling
molecules in NF-kB and MAPK pathways in TLR-triggeredptember 19, 2013 ª2013 Elsevier Inc. 473
Figure 3. Ash1l-SilencedMice AreMore Prone to
Spontaneous Systemic Autoimmune Disease
(A) ELISA assay of IgM, IgG1, IgG2a, IgG2b, IgG3, and
IgA in serum of 8-month-old WT and Ash1l-silenced
mice (n = 8 per genotype). A450 represented absor-
bance at 450 nm. Each symbol represents an individual
mouse and the small horizontal lines for the mean. *p <
0.05, **p < 0.01; NS, not significant.
(B) Hematoxylin and eosin staining of indicated organ
sections from 8-month-old WT and Ash1l-silenced
mice. Arrowheads indicate thickened capillarity loops.
Scale bars represent 50 mm.
(C) Kidney sections from 8-month-old WT and Ash1l-
silenced mice, stained with fluorescein isothiocyanate
(FITC)-labeled anti-mouse IgG. Scale bars represent
30 mm. Original magnification is 3200 (B and C).
These data sets are representative of three independent
experiments.
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Ash1l Is an Inhibitor of TLR ResponsesAsh1l-silenced macrophages. We observed enhanced phos-
phorylation of IKKa, IKKb, and their known substrates, IkBa and
NF-kB p65, as well as the MAPK kinases ERK, JNK, and p38 in
LPS-triggered Ash1l-silenced macrophages (Figure 5A; Table
S2). However, phosphorylation of IFN regulatory factor 3 (IRF3)
was similar between LPS-triggered Ash1l-silenced andWTmac-
rophages (Figure 5A; Table S2), in accordance with the intact
TLR-mediated IFN-b production by macrophages after Ash1l
silencing (Figure S1A). Consistently, Ash1l silencing resulted in
potently enhanced nuclear translocation of p65 but similar nu-
clear translocation of IRF3 (Figure 5B). We also obtained similar
results with Ash1l-silencedmacrophages triggered with poly(I:C)
(FiguresS4A andS4B; TableS3). It hasbeen shown that conjuga-
tion of lysine 63 (K63)-linked polyubiquitination chains to NEMO
and TRAF6 is required for the activation of NF-kB and MAPK
resulting in the downstream production of IL-6 (Chen, 2012).
Consistent with the enhanced NF-kB and MAPK signals, we
observed increased K63-ubiquitination on NEMO and TRAF6 in474 Immunity 39, 470–481, September 19, 2013 ª2013 Elsevier Inc.TLR-triggered Ash1l-silenced macrophages
(Figure 5C; Figure S4C).
Furthermore, deficiency of Ash1l also re-
sulted in the enhanced NF-kB and MAPK acti-
vation in macrophages in response to TNF
stimulation (FiguresS4DandS4E). InL929cells
that are sensitive to TNF stimulation, silencing
of Ash1l led to the increased apoptosis upon
TNF stimulation (Figures S4F). Thus Ash1l is
also involved in the negative regulation of
TNF-induced immune response and cell death.
Together, these data suggest that Ash1l
plays as a suppressor in TLR- and TNF-trig-
gered immune response by controlling the
key signal transduction of IL-6 production.
Ash1l Suppresses TLR Signals and IL-6
Production through H3K4
Methyltransferase Activity of Its SET
Domain
Next, we confirmed the inhibitory effect of
Ash1l on the translocation and activation ofNF-kB with overexpression analysis. The cDNA length of mouse
Ash1l is nearly 9 kb, making it extremely difficult to construct a
full-length vector. Instead, we constructed Ash1l-fragment 1, 2,
3 vectors respectively encoding 1–880 amino acids (aa), 881–
1,885aa, and 1,886–2,958aa of Ash1l (Figure S4G). Notably, re-
introduction of Ash1l-fragment 3 vector containing SET domain
into HEK293 cells attenuated NF-kB and IL-6 luciferase activity,
whereas reintroduction of Ash1l-fragment 1 and fragment 2
vectors had no such significant effect (Figure S4H). None of
the three vectors had any effect on IFN-b activity (Figure S4H).
Therefore, we predicted that Ash1l could suppress TLR-trig-
gered innate inflammatory response via its 1,886–2,958aa frag-
ment, which contains a SET domain.
The SET domain has been considered as the signature motif
of lysine-specific histone methyltransferase (HMTases) and
tightly associated with Ash1l’s function on transcriptional activa-
tion. Thus, we next investigated whether Ash1l negatively regu-
lated innate inflammatory response dependent on its H3K4
Figure 4. Increased Susceptibility of Ash1l-
Silenced Mice to Collagen-II Induced
Arthritis
(A–D) CIA was induced in WT and Ash1l-silenced
mice (n = 10 per genotype) and monitored for
disease development 3 weeks after first immuni-
zation as follows: (A) Percentage of WT and
Ash1l-silenced mice developing arthritis. (B) The
average diameter of ankle joints. (C) Clinical
scores of WT and Ash1l-silenced mice, evaluated
as described in Supplemental Experiment Pro-
cedures. Error bars represent SD. *p < 0.05.
(D) Hematoxylin and eosin staining of knee joints
from WT and Ash1l-silenced mice. *, mononuclear
cells infiltration; :, cartilage erosion or new bone
formation. Scale bars represent 100 mm. Original
magnification 350.
(E–H) CIA was induced in WT mice, Ash1l-silenced
mice, Il6/ mice, and Ash1l-silenced Il6/
double-mutant mice (n = 10 per genotype). The
development of diseases was monitored and
evaluated as described in (A)–(D). (E) Percentage of
mice developing arthritis. (F) The average diameter
of ankle joints. (G) Clinical scores of mice from four
groups. Error bars represent SD. *p < 0.05. (H)
Hematoxylin and eosin staining of knee joints. :,
cartilage erosion or new bone formation. Scale bars
represent 100 mm. Original magnification 350.
These data sets are representative of three inde-
pendent experiments. Related to Figure S3 and
Table S2.
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Ash1l Is an Inhibitor of TLR Responsesmethyltransferase activity of SET domain. In this regard, it has
been reported that a single amino acid point mutation
Ash16N10 (N1458I) in the SET domain of the Drosophila Ash1
abolishes its HMTase activity (Beisel et al., 2002). With homolo-
gous comparison, we found that this amino acid residue was
equivalent to the amino acid 2212 in the mouse Ash1l. We then
constructed this single amino acid point mutation Ash1l6N
(N2212I) (Figure S4G). HMTase assays revealed that H3K4
methytransferase activity was abolished in the Ash1l6N
(N2212I) mutant (Figure S4I).
Overexpression of Ash1l-fragment 3 containing the SET
domain, but not Ash1l-fragment 1, 2, or mutant vector, attenu-
ated TNF-stimulated nuclear translocation of p65 in HEK293
cells (Figure S4J), which indicated that the SET domain is
essential for the suppressive effect of Ash1l on the key signal
transduction of IL-6 production. To further confirm that, we
transfected Ash1l-silenced and WT macrophages with Ash1l-
fragment 3 vector or Ash1l6N (N2212I) mutant vector,
respectively. We observed that overexpression of Ash1l-frag-
ment 3 vector reduced the phosphorylation of p65 and MAPKImmunity 39, 470–481, Srelative to that in mock-transfected con-
trol cells in TLR-triggered WT macro-
phages and reversed the more activated
TLR-triggered downstream signals in
Ash1l-silenced macrophages, whereas
overexpression of Ash1l6N (N2212I)
mutant vector had no such effect, which
indicated that Ash1l indeed suppresses
TLR signals dependent on its H3K4 meth-yltransferase activity of SET domain (Figure 5D; Figure S4K;
Tables S4 and S5).
Nuclear p65 serves as a critical transcriptional factor for
IL-6 expression, and phosphorylated MAPK is also indis-
pensable for induction of IL-6. We next investigated whether
the H3K4 methyltransferase activity of SET domain was
required for suppressing the excessive production of IL-6
and TNF in TLR-triggered Ash1l-silenced macrophages. We
observed that overexpression of Ash1l-fragment 3 potently
suppressed the production of IL-6 and TNF in TLR-triggered
WT macrophages relative to that in mock-transfected con-
trol cells and substantially reversed the excessive production
of IL-6 and TNF in TLR-triggered Ash1l-silenced macro-
phages (Figure 5E). However, none of Ash1l-fragment 1, frag-
ment 2 vectors, or Ash1l6N (N2212I) mutant vector had such
effects.
Collectively, these data suggest that Ash1l negatively regu-
lates TLR-triggered IL-6 production through suppressing
NF-kB and MAPK signals dependent on its SET domain-medi-
ated H3K4 methyltransferase activity.eptember 19, 2013 ª2013 Elsevier Inc. 475
Figure 5. Ash1l Suppresses Activation of
TLR Signals and IL-6 Production via H3K4
Methyltransferase Activity of Its SET
Domain
(A) Immunoblot analysis (IB) of the phosphorylated
(p-) or total protein in lysates of WT and Ash1l-
silenced macrophages stimulated for 0–240 min
with LPS. Total protein and b-actin serve as
loading controls.
(B) IB of p65 and IRF3 in nuclear extracts of WT
and Ash1l-silenced macrophages stimulated for
0–4 hr with LPS. Lamin A serves as a loading
control.
(C) IB of K63-ubiquitination in lysates of WT
and Ash1l-silenced macrophages stimulated for
0–90 min with LPS and immunoprecipitated (IP)
with antibody to NEMO (top) and TRAF6
(bottom), respectively. IP with immunoglobulin
(IgG) serves as an IP control (Ctrl). IB of NEMO and
TRAF6 in total cell lysates serve as a loading
control.
(D) IB of phosphorylated or total protein in lysates
of WT and Ash1l-silenced macrophages mock-
transfected or transfected with Ash1l-fragment 3
(1,886–2,958aa) vector or Ash1l6N (N2212I)
mutant vector, respectively, stimulated with LPS
for 1 hr.
(E) CBA assay of IL-6 and TNF in supernatants of
WT and Ash1l-silenced macrophages transfected
with Ash1l-fragment 1 (1–880aa), Ash1l-fragment
2 (881–1,885aa), Ash1l-fragment 3 (1886–2,958aa)
vectors or Ash1l6N (N2212I) mutant vector and
stimulated for 8 hr with LPS or poly(I:C). Error bars
represent SD. *p < 0.05, **p < 0.01, NS, not sig-
nificant. These data sets are representative of
three independent experiments. Related to Fig-
ure S4 and Table S4.
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Ash1l Is an Inhibitor of TLR ResponsesAsh1l Suppresses TLR Signaling and IL-6 Production by
Facilitating A20 Expression via Its SET Domain
Ash1l acts as a H3K4 methytransferase that is linked with tran-
scriptional activation of targeted genes. However, our findings
above indicated that Ash1l negatively regulates innate IL-6 pro-
duction. Thus, we propose that Ash1l might be involved in the
transcriptional activation of genes encoding certain negative
regulators of TLR signals. To confirm this hypothesis, we next
selected several well-known inhibitors of TLR signals and
analyzed their expression in Ash1l-silenced macrophages.
Quantitative PCR revealed that LPS stimulation induced compa-
rable expression of signaling inhibitors such as SOCS1, SOCS3,
SHP-1, RKIP, and Mkp1 between Ash1l-silenced and WT
macrophages (Figure S5A). Interestingly, A20 expression was
reduced in Ash1l-silenced macrophages upon LPS and poly(I:C)
stimulation as compared to WT macrophages (Figures S5A; Fig-
ure 6A). Nuclear run on experiment showed that nascent Tnfaip3
messenger RNA (mRNA) produced at 30 and 60 min after LPS
stimulation was reduced in Ash1l-silenced macrophages, high-
lighting that Ash1l could directly drive Tnfaip3 transcription
(Figure 6B). We also detected the reduced Tnfaip3 mRNA476 Immunity 39, 470–481, September 19, 2013 ª2013 Elsevier Inc.expression in RAW264.7 cells after
Ash1l silencing (Figure S5B). However,
the expression of PPIA, EEF1A1, andRPLP0, which were proved to be Ash1l-occupied active genes
in resting HeLa cells (Gregory et al., 2007), was not affected after
silencing of Ash1l (Figure S5B).
To further confirm the involvement of Ash1l in A20 expres-
sion, we transfected Ash1l-silenced and WT macrophages
with expression vectors encoding Ash1l-fragment 3 or
Ash1l6N (N2212I) mutant. Overexpression of Ash1l-fragment
3 potently rescued the attenuated expression of A20 in
TLR-triggered Ash1l-silenced macrophages, whereas overex-
pression of Ash1l6N (N2212I) mutant had no such effect (Fig-
ure 6C), indicating that the upregulation of A20 expression was
dependent on H3K4 methyltransferase activity of Ash1l SET
domain.
A20 inhibits TLR-triggered IL-6 production through deubiqui-
tinating K63-linked polyubiquitination chain on various sub-
strates such as TRAF6 and NEMO (Boone et al., 2004). Given
the deficient deubiquitination of K63-linked ubiquitination on
NEMO and TRAF6 as well as attenuated expression of A20
in TLR-triggered Ash1l-silenced macrophages, we therefore
wondered whether Ash1l suppresses TLR signals by facilitating
A20-mediated NEMO and TRAF6 deubiquitination. We found
Figure 6. Ash1l Enhances A20 Expression
via SET Domain to Suppresses TLR
Signaling and IL-6 Production
(A) Expression of A20 in WT and Ash1l-silenced
macrophages stimulated with LPS (top) or
poly(I:C) (bottom).
(B) Nascent Tnfaip3 mRNA in WT and Ash1l-
silenced macrophages stimulated with LPS for 30
or 60 min. Error bars represent SD. *p < 0.05.
(C) Expression of A20 in WT and Ash1l-silenced
macrophages transfected with Ash1l-fragment
3 (1,886–2,958aa) vector or Ash1l6N(N2212I)
mutant vector, and stimulated with LPS or
poly(I:C) for 1 hr. b-actin serves as a loading
control.
(D) IB of K63-ubiquitination in lysates of WT and
Ash1l-silenced macrophages mock-transfected
or transfected with plasmid encoding A20, stimu-
lated for 45 min with LPS or poly(I:C) and then
immunoprecipitated (IP) with antibody to NEMO
(top) and TRAF6. IP with IgG serves as an IP
control (Ctrl). NEMO and TRAF6 in total cell lysates
serve as a loading control.
(E) CBA assay of IL-6 and TNF in supernatants of
WT and Ash1l-silenced macrophages transfected
as in (C), and stimulated for 8 hr with LPS or
poly(I:C). Error bars represent SD. **p < 0.01.
These data sets are representative of three inde-
pendent experiments. Related to Figure S5.
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ubiquitination on both NEMO and TRAF6 in TLR-triggered
WT macrophages relative to that in mock-transfected con-
trol cells and substantially restored the impaired K63-
deubiquitination in TLR-triggered Ash1l-silenced macrophages
to amount similar to that in WT macrophages (Figure 6D).
Deubiquitination on NEMO and TRAF6 mediated by A20
serves as a key step for inhibition of IL-6 production. Therefore,
we wondered whether the excessive IL-6 production along
with the impaired deubiquitination in TLR-triggered Ash1l-
silenced macrophages was also due to the reduced A20
expression. Indeed, overexpression of A20 suppressed the
production of IL-6 and TNF in TLR-triggered WT macro-
phages relative to that in mock-transfected control cells and
consistently reversed the excessive production of IL-6 and
TNF in TLR-triggered Ash1l-silenced macrophages (Figures
6E). Therefore, these data indicate that Ash1l negatively regu-
lates TLR-triggered IL-6 production and innate inflammatory
responses by directly facilitating A20 expression via the SET
domain.Immunity 39, 470–481, SeAsh1l Enhances TLR-Stimulated
A20 Expression via Inducing
H3K4me3 Modification at the
Tnfaip3 Promoter
The data presented above indicate that
Ash1l could facilitate A20 expression
upon TLR stimulation. Because Ash1l
acts as an intrinsic multicatalytic
HMTase that can catalyze the conver-
sion of H3K4me1 (monomethylated) to
H3K4me3 (trimethylated), we wonderedwhether Ash1l could directly target the Tnfaip3 gene and elevate
H3K4me3 modification at the Tnfaip3 promoter to enhance A20
expression via its HMTase activity. Chromatin immunoprecipita-
tion (ChIP) experiments with antibody to Ash1l revealed that
Ash1l was enriched at the Tnfaip3 promoter region but not Il6
or Tnf promoter region in macrophages upon LPS or poly(I:C)
stimulation (Figures 7A and 7B). Furthermore, we did not observe
recruitment of Ash1l to the promoter regions of other TLR-
induced active genes including NFkb1, Ifnb, Il12b, Mkp1 and
Jmjd3, after LPS stimulation, which implied that Ash1l is selec-
tively bound to the Tnfaip3 promoter among those selected
genes (Figure S6A). We next tried to investigate how TLR signals
induced the selective enrichment of Ash1l to the Tnfaip3 pro-
moter. We wondered whether some transcriptional factors at
the Tnfaip3 promotermight be involved in recruiting and interact-
ing with Ash1l. Sp-1 was selected as a candidate because Sp-1
silencing led to the reduced Tnfaip3 mRNA expression in
LPS-stimulated macrophages (Figure S6B). However, coIP ex-
periments revealed no interaction between Ash1l and Sp-1
upon LPS stimulation (Figure S6C). Notably, a DNase I sensitivityptember 19, 2013 ª2013 Elsevier Inc. 477
Figure 7. Ash1l Accumulates at Tnfaip3
Promoter and Elevates Its H3K4me3 Modifi-
cation in Response to TLR Ligands
(A and B) ChIP analysis of the recruitment of Ash1l
to the Tnfaip3, Il6, and Tnf promoter regions with
anti-Ash1l antibody in macrophages stimulated for
1 hr with LPS or poly(I:C). Tnfaip3, Il6, and Tnf
promoter sequences in input DNA and DNA
recovered from antibody-bound chromatin seg-
ments were detected by quantitative PCR (A) or
semiquantitative PCR (B). IgG serves as a ChIP
control and Input as normalized control.
(C) Chromatin accessibility of the Tnfaip3 promoter
region by quantitative RT-PCR with DNase I
pretreated nucleus of WT and Ash1l-silenced
macrophages stimulated with LPS or poly(I:C) for
1 hr. Results were presented as changed fold
concluded with 2DCt, with relative to WT macro-
phages without stimulation, set as 1.
(D and E) H3K4me3 modifications of the Tnfaip3,
Il6, and Tnf promoter regions. CHIP analysis of the
trimethylation of histone H3 lysine 4 (H3K4me3) at
the Tnfaip3, Il6, and Tnf promoter regions in WT
and Ash1l-silenced macrophages stimulated as in
(A) and (B). Promoter sequences were detected by
quantitative PCR (D) or semiquantitative PCR (E).
Error bars represent SD. **p < 0.01, *p < 0.05, NS,
not significant. These data sets are representative
of three independent experiments. Related to
Figure S6.
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promoter was more significantly increased in WT macrophages
compared to that in Ash1l-silenced macrophages upon TLR
stimulation, indicating that Ash1l is involved in loosening of
chromatin structure of the Tnfaip3 promoter (Figure 7C).
Hence the selectivity of Ash1l recruitment to the Tnfaip3
promoter might be due to the regulation of chromatin structure
of the Tnfaip3 promoter by Ash1l, which requires further
investigation.
Finally, we assessed the H3K4me3 modification of Tnfaip3,
Il6, and Tnf promoter regions in TLR-triggered Ash1l-silenced
andWTmacrophages. ChIP with antibody to H3K4me3 revealed
that TLR ligands induced an increase of H3K4me3 modifica-
tion at the promoter regions of Tnfaip3, Il6, and Tnf. However,
only the promoter region of Tnfaip3 had a lower concentration
of H3K4me3 modification in Ash1l-silenced macrophages com-
pared with WT macrophages (Figures 7D and 7E), suggesting
that Ash1l selectively mediated H3K4me3 at Tnfaip3 promoter
regions. These data demonstrate that Tnfaip3 is one of the
Ash1l target genes in macrophages and suggest that Ash1l478 Immunity 39, 470–481, September 19, 2013 ª2013 Elsevier Inc.enhances Tnfaip3 expression through
binding to the Tnfaip3 promoter and
increasing its H3K4 modification.
DISCUSSION
Epigenetic modifications such as his-
tone modifications become increasingly
involved in the transcriptional regulation
of multiple TLR-inducible genes. Forexample, H3K4 modification is induced by LPS stimulation at
the promoter of Il12b, which promotes the production of IL-
12p40, a proinflammatory cytokine associated with multiple
immunological processes (Kayama et al., 2008). Considering
that enzymes modifying H3K4 methylation might be involved in
the regulation of TLR-triggered cytokine production, in this
study, we performed the siRNA screening test of 14 known
H3K4 methyltransferases or demethylases and found that Mll1
andMll4 could upregulate LPS-induced IL-6 production, consis-
tent with previous studies (Wang et al., 2012; Austenaa et al.,
2012). Mll2 was also found to promote LPS signals. On the
contrary, we found that Ash1l and Kdm5a could downregulate
LPS-triggered signals, which was not reported previously.
Because Ash1l is a well-characterized H3K4 methyltransfer-
ase that is associated with transcriptional activation, our dis-
covery of its role in the inhibition of TLR signaling sheds new light
on the flexible function of methyltransferases. Ash1l was initially
discovered by screening of imaginal disc mutants in Drosophila
melanogaster (Shearn et al., 1978). A recent study reported the
mutations in Ash1l gene in 9 of 19 tested cancer cell lines, which
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immunity (Liu et al., 2012). Here we demonstrate that Ash1l
negatively regulates TLR-triggered production of proinflamma-
tory cytokines and inflammatory autoimmune disease by
suppressing NF-kB and MAPK pathways via its H3K4 methyl-
transferase activity of the SET domain.
Furthermore, we identified Tnfaip3 as a new target gene of
Ash1l and showed that Ash1l suppresses TLR-mediated IL-6
and TNF production by promoting A20 expression. Human
genetic studies have linked germline single-nucleotide polymor-
phisms (SNPs) of Tnfaip3 with susceptibility to multiple human
diseases, such as SLE and RA (Shimane et al., 2010). Indeed,
Ash1l-silenced mice showed higher susceptibility to sponta-
neous autoimmune pathogenesis and collagen-II induced
arthritis imitating human RA, resembling the phenotype of A20
conditional-deficient mice, indicating that Ash1l indeed main-
tained immune balance through promoting A20 activity. In this
study, we found that A20 overexpression in Ash1l-silenced cells
reversed enhancement of IL-6 production and NF-kB activation.
It will be intriguing to investigate whether Ash1l-silenced-
Tnfaip3-transgenic mice can rescue the autoimmune phenotype
in Ash1l-silenced mice in the future.
Acting as a master regulator in TLR signals, A20 is required
to be subtly regulated to achieve assuring inflammatory re-
sponses at an appropriate intensity and duration, therefore, it
is also necessary to understand the regulation of A20 expres-
sion and activity. Various transcription factors and coactivators,
such as Sp-1, CBP, and p300, have been suggested to be
involved in the rapid induction of the Tnfaip3 gene upon TNF
stimulation (Ainbinder et al., 2002), and various posttransla-
tional modifications of A20, such as phosphorylation and
ubiquitylation, serve to restrict its activity (Hutti et al., 2007;
Coornaert et al., 2008). However, it remains unclear whether
and how epigenetic especially histone modifications are
involved in the regulation of A20. In this study, we have demon-
strated that the trimethylation concentration at Tnfaip3 pro-
moter can be enhanced in TLR-triggered macrophages by
accumulation of Ash1l, a member of H3K4 methyltransferase.
And thus Ash1l directly regulates A20 expression through his-
tone modification, shedding an insight into the regulation of
A20 expression. During the study, we also found elevated tri-
methylation concentrations at both Il6 and Tnf promoter upon
TLR stimulation, which suggested that histone modifications
are also involved in proinflammatory cytokine production. How-
ever, TLR-triggered trimethylation of Il6 and Tnf promoter were
not mediated by Ash1l shown as no difference between WT and
Ash1l-silenced macrophages.
Themethyltransferase activity of Ash1l has been the subject of
controversy. Though some reported that Ash1l could trimethy-
late H3K4, H3K9, H3K36, andH4K20 (Tanaka et al., 2011), in vivo
studies provided evidence that Ash1l is H3K4 selective and acts
as a potent transcription activator (Byrd and Shearn, 2003;
Gregory et al., 2007). Here in our study, we found that the SET-
domain-containing fragment of Ash1l had H3K4 methyltransfer-
ase activity. Thus, although Ash1l might have been a candidate
enzyme for methylation of H3K4, H3K9, H3K36, and H4K20,
we focused on themain andmore compelling H3K4methyltrans-
ferase activity of Ash1l. Moreover, we confirmed that Ash1l
indeed could activate A20 expression by enhancing the H3K4Immodification at Tnfaip3 promoter, which was dependent on its
H3K4 methyltransferase activity.
Collectively, we have demonstrated that Ash1l negatively reg-
ulates TLR-triggered innate inflammatory response through sup-
pressing the K63-linked deubiquitination on NEMO and TRAF6
and subsequently activation of NF-kB and MAPK signals.
Ash1l can accumulate at the Tnfaip3 promoter, enhance its
H3K4 methylation modification, and hence activate A20 expres-
sion upon TLR stimulation. Thus Ash1l acts as a suppressor of
TLR signaling through inducing A20 expression, in a manner
dependent on the H3K4 methyltransferase activity of its SET
domain. Our study has identified Ash1l as a negative regulator
of innate inflammatory immune response and provides mecha-
nistic insight into A20 induction and regulation. More impor-
tantly, our findings provide the insightful elucidation of the
association of specific histone modification enzymes with TLR-
triggered innate immune responses and important clues for the
intervention of inflammatory and autoimmune diseases.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies, Measurement of Serum Immunoglobulin, RNA-
Mediated Interference, Quantitative RT-PCR, Immunoprecipitation and
Immunoblot Analysis, Confocal Microscopy, Plasmid Constructs, Flow
Cytometry, DNase I Sensitivity Analysis, Nuclear Run-on Experiment, Assay
of Luciferase Reporter Gene Expression, In Vitro Histone Methyltransferase
Activity Assay, and detailed experimental procedures can be found in Supple-
mental Experimental Procedures.
Animal Experiments
Ash1l-silenced mice were generated with the PB transposon insertion (Ding
et al., 2005) between exons 15 and 16 of Ash1l allele in male germline and
bred under pathogen-free conditions. Ash1l-silenced mice on FVB back-
ground were consistently crossbred (12 generations) onto a C57BL/6J back-
ground, and then were bred with Il6/ mice (B6.129S6-Il6tm1Kopf/J; 002650;
Jackson Laboratory) to generate Ash1l-silenced Il6/ double-mutant mice.
Six- to eight-week-old littermate mice were used. All animal experiments
were performed in accordance with the National Institutes of Health Guide
for the Care and Use of Laboratory Animals, with the approval of the Scientific
Investigation Board of Second Military Medical University, Shanghai.
Cell Culture and Cytokine Assay
Thioglycolate-elicited mouse peritoneal macrophages were cultured in RPMI-
1640 medium with 10% (vol/vol) FCS at a density of 2 3 105 cells per ml for
cytokine assay and 1 3 106 cells per ml for immunoblot analysis (Xu et al.,
2012). Bone-marrow-derived macrophages (BMDMs) were generated with
recombinant mouse GM-CSF (10 ng/ml). After 5 days, cells were replated
and stimulated with LPS (100 ng/ml) or poly (I:C) (10 ug/ml). Amounts of IL-6
and TNF in supernatants and sera were measured by cytometric bead
array immunoassay (CBA; BD Biosciences) according to the manufacturer’ s
protocol.
Chromatin Immunoprecipitation Assay
ChIP assays were conducted with a ChIP Assay Kit (Millipore) according to the
manufacturer’s protocol as described before (Chen et al., 2013). Detailed
assay can be found in Supplemental Experimental Procedures.
Establishment of Mouse Models for Endotoxin Shock and Bacterial
Infection
WT and Ash1l-silenced mice were injected intraperitoneally with LPS (15 mg
per kg body weight), poly(I:C) (20 mg per kg body weight), or 1 3 108 E. coli
strain O111:B4. Sera were collected and measured by CBA for cytokine con-
centrations. Colony-forming units (cfu) were measured by counting of viable
bacteria on agar plates in blood samples.munity 39, 470–481, September 19, 2013 ª2013 Elsevier Inc. 479
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CIA was induced as previously described with minor modifications (Alonzi
et al., 1998). Detailed procedures can be found in Supplemental Experimental
Procedures.
Statistical Analysis
The statistical significance between two groups was determined by Student’s
t test. The statistical significance of survival curves were estimated with the
method of Kaplan-Meier, and curves were compared with the generalized
Wilcoxon test. p values of less than 0.05 were considered statistically signifi-
cant (*p < 0.05, **p < 0.01).
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, five tables, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.immuni.2013.08.016.
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